Publikace a výsledky VaV

Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response.

Pazdirek F, Minarik M, Benesova L, Halkova T, Belsanova B, Macek M, Stepanek L, Hoch J.

Front Oncol. 2020;10:1028.

Circulating tumor DNA as a biomarker  in metastatic colorectal carcinoma case report.

Menclova K, Pudil J, Benesova L, Halkova T, Ptackova R, Semyakina A, Minarik M, Levy M, Simsa J, Pazdirek F, Hoch J, Blaha M, Ryska M.

Rozhl Chir. 2020;99(4):179-182. English.

Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer.

Benesova L, Halkova T, Bunganic B, Belsanova B, Zavoral M, Traboulsi E, Minarik M.

Pathol Oncol Res. 2020;26(1):379-385.

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.

Benesova L, Halkova T, Ptackova R, Semyakina A, Menclova K, Pudil J, Ryska M, Levy M, Simsa J, Pazdirek F, Hoch J, Blaha M, Minarik M.

World J Gastroenterol.2019;25(48):6939-6948.

Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.

Benesova L, Belsanova B, Kramar F, Halkova T, Benes V, Minarik M.

J Sep Sci. 2018 Jul;41(13):2819-2827.

[Patient with Three EGFR Mutations – Gradual Development of Resistance to Previous Targeted Treatment].

Svatoň M, Pešek M, Baxa J, Mukenšnabl P, Benešová L, Minárik M.

Klin Onkol. Winter 2017;31(1):53-58.

Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.

 Fiala O, Hosek P, Pesek M, Finek J, Racek J, Stehlik P, Sorejs O, Minarik M, Benesova L, Celer A, Nemcova I, Kucera R, Topolcan O.

Anticancer Res. 2017 Nov;37(11):6469-6476.

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery.

Vojtechova G, Benesova L, Belsanova B, Minarikova P, Levy M, Lipska L, Suchanek S, Zavoral M, Minarik M.

Adv Clin Exp Med. 2016 Nov-Dec;25(6):1273-1279.

The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature.

Repak R, Kohoutova D, Podhola M, Rejchrt S, Minarik M, Benesova L, Lesko M, Bures J.

Gastrointest Endosc. 2016 Oct;84(4):718-25. 

Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.

Minarikova P, Benesova L, Halkova T, Belsanova B, Suchanek S, Cyrany J, Tuckova I, Bures J, Zavoral M, Minarik M.

World J Gastroenterol. 2016 May 28;22(20):4936-45. 

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T.

Anticancer Res. 2016 May;36(5):2459-65.

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O.

Anticancer Res. 2016 Mar;36(3):1077-82.

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.

Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):455-60.

Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.

Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):447-53.

[KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].

Bunganič B, Hálková T, Benešová L, Belšánová B, Laclav M, Hrůzová M, Traboulsi E, Frič P, Suchánek Š, Minárik M, Zavoral M.

Cas Lek Cesk. 2016;155(1):48-51. Czech.

IDH1/2 Mutation and MGMT Promoter Methylation – the Relevant Survival Predictors in Czech Patients with Brain Gliomas.

Kramář F, Minárik M, Benešová L, Halková T, Netuka D, Bradáč O, Beneš V.

Folia Biol (Praha). 2016;62(5):194-202.

High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Minarik M, Benesova L, Bortlicek Z, Poprach A, Buchler T.

Tumour Biol. 2015 Dec;36(12):9215-22. 

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.

Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Bortlicek Z, Topolcan O.

Tumour Biol. 2015 Aug;36(8):5801-5. 

Variants in miRNA regulating cardiac growth are not a common cause of hypertrophic cardiomyopathy.

Curila K, Benesova L, Tomasov P, Belsanova B, Widimsky P, Minarik M, Zemanek D, Veselka J, Gregor P.

Cardiology. 2015;130(3):137-42. 

MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis.

Halkova T, Cuperkova R, Minarik M, Benesova L.

Gastroenterol Res Pract. 2015;2015:892903. 

The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Sep;34(9):5193-8. Erratum in: Anticancer Res. 2014 Nov;34(11):6859.

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, Topolcan O.

Anticancer Res. 2014 Jun;34(6):3205-10.

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.

Fiala O, Pesek M, Finek J, Krakorova G, Benesova L, Minarik M.

Tumori. 2014 May-Jun;100(3):e70-3. 

Genetic testing in the management of relatives of patients with hypertrophic cardiomyopathy.

Tomašov P, Minárik M, Zemánek D, Čadová P, Homolová S, Čurilka K, Pěnička M, Benešová L, Belšánová B, Gregor P, Veselka J.

Folia Biol (Praha). 2014;60(1):28-34.

Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Anticancer Res. 2013 Aug;33(8):3397-402.

Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.

Paulu P, Osmancik P, Tousek P, Minarik M, Benesova L, Motovska Z, Bednar F, Kocka V, Widimsky P.

J Thromb Thrombolysis. 2013 Jul;36(1):1-6. 

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Anticancer Res. 2013 Apr;33(4):1705-11.

Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients.

Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, Levy M, Visokai V, Zavoral M, Minarik M.

Anal Biochem. 2013 Feb 15;433(2):227-34. 

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.

Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. 

Erlotinib in the treatment of advanced squamous cell NSCLC.

Fiala O, Pesek M, Finek J, Krejci J, Havel L, Hrnciarik M, Salajka F, Bortlicek Z, Benesova L, Minarik M.

Neoplasma. 2013;60(6):676-82. 

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M.

Neoplasma. 2013;60(4):425-31. 

Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.

Fiala O, Pesek M, Finek J, Krejci J, Bortlicek Z, Benesova L, Minarik M.

Neoplasma. 2013;60(2):129-34.

Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.

Fiala O, Pesek M, Finek J, Krejci J, Ricar J, Bortlicek Z, Benesova L, Minarik M.

Neoplasma. 2013;60(1):26-32. 

Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients.

Levy M, Benesova L, Lipska L, Belsanova B, Minarikova P, Veprekova G, Zavoral M, Minarik M.

Anticancer Res. 2012 May;32(5):1621-6.

Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.

Minarik M, Kopeckova M, Gassman M, Osmancik P, Benesova L.

Electrophoresis. 2012 Apr;33(8):1306-10. 

Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy.

Curila K, Benesova L, Penicka M, Minarik M, Zemanek D, Veselka J, Widimsky P, Gregor P.

Acta Cardiol. 2012 Feb;67(1):23-9.

[EGFR mutations in patients with advanced NSCLC].

Fiala O, Pešek M, Fínek J, Brůha F, Bortlíček Z, Krejčí J, Benešová L, Minárik M.

Klin Onkol. 2012;25(4):267-73. Czech.

Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease.

Pesek M, Kopeckova M, Benesova L, Meszarosova A, Mukensnabl P, Bruha F, Minarik M.

Anticancer Res. 2011 Dec;31(12):4647-52.

Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification.

Krejci J, Pesek M, Grossmann P, Krejci M, Ricar J, Benesova L, Minarik M.

Cancer Genomics Proteomics. 2011 May-Jun;8(3):135-8.

A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA.

Minarik M, Gassman M, Belsanova B, Pesek M, Schouten J, Chudoba R, Gas B, Benesova L.

Electrophoresis. 2010 Oct;31(21):3518-24. 

Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.

Benesova L, Pesek M, Belsanova B, Sekerka P, Minarik M.

J Sep Sci. 2010 Aug;33(15):2349-55. 

36. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

Benesova L, Minarik M, Jancarikova D, Belsanova B, Pesek M.

Anticancer Res. 2010 May;30(5):1667-71.

Assembly of a large Y-STR haplotype database for the Czech population and investigation of its substructure.

Zastera J, Roewer L, Willuweit S, Sekerka P, Benesova L, Minarik M.

Forensic Sci Int Genet. 2010 Apr;4(3):e75-8. 

Low prevalence and variable clinical presentation of troponin I and troponin T gene mutations in hypertrophic cardiomyopathy.

Curila K, Benesova L, Penicka M, Minarik M, Zemanek D, Veselka J, Widimsky P, Gregor P.

Genet Test Mol Biomarkers. 2009 Oct;13(5):647-50. 

Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.

Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F, Minarik M.

Anticancer Res. 2009 Jul;29(7):2767-73.

Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.

Salek C, Minarikova P, Benesova L, Nosek V, Strnad R, Zavoral M, Minarik M.

Anticancer Res. 2009 May;29(5):1803-10.

Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.

Salek C, Benesova L, Zavoral M, Nosek V, Kasperova L, Ryska M, Strnad R, Traboulsi E, Minarik M.

World J Gastroenterol. 2007 Jul 21;13(27):3714-20.

Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.

Jancarikova D, Pesek M, Benesova L, Topolcan O, Holubec L Jr, Minarik M.

Anticancer Res. 2007 Jul-Aug;27(4A):1879-82.

Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer.

Trkova M, Babjuk M, Duskova J, Benesova-Minarikova L, Soukup V, Mares J, Minarik M, Sedlacek Z.

Cancer Lett. 2006 Oct 8;242(1):68-76.

Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections.

Minarik M, Benesova L, Fantova L, Horacek J, Heracek J, Loukola A.

Electrophoresis. 2006 Oct;27(19):3856-63.

Multicapillary electrophoresis of unlabeled DNA fragments with high-sensitive laser-induced fluorescence detection by counter-current migration of intercalation dye.

Benesova-Minarikova L, Fantova L, Minarik M.

Electrophoresis. 2005 Nov;26(21):4064-9.

 Application of cycling gradient capillary electrophoresis to detection of APC, K-ras, and DCC point mutations in patients with sporadic colorectal tumors.

Minarik M, Minarikova L, Hrabikova M, Minarikova P, Hrabal P, Zavoral M.

Electrophoresis. 2004 Apr;25(7-8):1016-21.

Cycling gradient capillary electrophoresis: a low-cost tool for high-throughput analysis of genetic variations.

Minarik M, Minarikova L, Bjørheim J, Ekstrøm PO.

Electrophoresis. 2003 Jun;24(11):1716-22.

Ammonia pulses and metabolic oscillations guide yeast colony development.

Palková Z, Devaux F, Icicová M, Mináriková L, Le Crom S, Jacq C.

Mol Biol Cell. 2002 Nov;13(11):3901-14.

Differentiated gene expression in cells within yeast colonies.

Mináriková L, Kuthan M, Ricicová M, Forstová J, Palková Z.

Exp Cell Res. 2001 Dec 10;271(2):296-304.